The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Imatinib Mesylate as Add-on Therapy for Pulmonary Arterial Hypertension: Results of the Randomized IMPRES Study
Abstract
Background—: By its inhibitory effect on platelet-derived growth factor signaling, imatinib could be efficacious in treating patients with pulmonary arterial hypertension (PAH). Methods and Results—: Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study (IMPRES), a randomized, double-blind, placebo-controlled 24-week trial, evaluated imatinib in patients with pulmonary vascular resistance ≥800 dyne·s·cm −5 symptomatic on ≥2 PAH therapies. The primary outcome was change in 6-minute walk distance. Secondary outcomes included changes in hemodynamics, functional class, serum levels of N-terminal brain natriuretic peptide, and time to clinical worsening. After completion of the core study, patients could enter an open-label long-term extension study. Of 202 patients enrolled, 41% patients received 3 PAH therapies, with the remainder on 2 therapies. After 24 weeks, the mean placebo-corrected treatment effect on 6-minute walk distance was 32 m (95% confidence interval, 12–52; P =0.002), an effect maintained in the extension study in patients remaining on imatinib. Pulmonary vascular resistance decreased by 379 dyne·s·cm −5 (95% confidence interval, −502 to − 255; P <0.001, between-group difference). Functional class, time to clinical worsening, and mortality did not differ between treatments. Serious adverse events and discontinuations were more frequent with imatinib than placebo (44% versus 30% and 33% versus 18%, respectively). Subdural hematoma occurred in 8 patients (2 in the core study, 6 in the extension) receiving imatinib and anticoagulation. Conclusions—: Imatinib improved exercise capacity and hemodynamics in patients with advanced PAH, but serious adverse events and study drug discontinuations were common. Further studies are needed to investigate the long-term safety and efficacy of imatinib in patients with PAH. Clinical Trial Registration—: URL: http://www.clinicaltrials.gov . Unique identifier: NCT00902174 (core study); NCT01392495 (extension).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ATS Statement: Guidelines for the Six-Minute Walk Test
(2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.166.1.at1102 · Cited by 11,195
Updated clinical classification of pulmonary hypertension
Simonneau, G., Gatzoulis, M. A., Adatia, I., Celermajer, D., Denton, C., Ghofrani, A., Gomez Sanchez, M. A., Krishna Kumar, R., Landzberg, M., Machado, R. F., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.10.029 · Cited by 4,191
Self-citationO'Brien, S. G., Guilhot, F., Larson, R. A., Gathmann, I., Baccarani, M., Cervantes, F., Cornelissen, J. J., Fischer, T., Hochhaus, A., Hughes, T., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022457 · Cited by 3,570
D'Alonzo, G. E., Barst, R. J., Ayres, S. M., Bergofsky, E. H., Brundage, B. H., Detre, K. M., Fishman, A. P., Goldring, R. M., Groves, B. M., Kernis, J. T., et al. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-115-5-343 · Cited by 3,501
Self-citationBosentan Therapy for Pulmonary Arterial Hypertension
Rubin, L. J., Badesch, D. B., Barst, R. J., Galiè, N., Black, C. M., Keogh, A., Pulido, T., Frost, A., Roux, S., Leconte, I., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012212 · Cited by 2,726
Self-citationBarst, R. J., Rubin, L. J., Long, W. A., McGoon, M. D., Rich, S., Badesch, D. B., Groves, B. M., Tapson, V. F., Bourge, R. C., Brundage, B. H., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602013340504 · Cited by 2,698
Self-citationSildenafil Citrate Therapy for Pulmonary Arterial Hypertension
Galiè, N., Ghofrani, H. A., Torbicki, A., Barst, R. J., Rubin, L. J., Badesch, D., Fleming, T., Parpia, T., Burgess, G., Branzi, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050010 · Cited by 2,476
Self-citationUpdated Clinical Classification of Pulmonary Hypertension
Simonneau, G., Robbins, I. M., Beghetti, M., Channick, R. N., Delcroix, M., Denton, C. P., Elliott, C. G., Gaine, S. P., Gladwin, M. T., Jing, Z.-C., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.04.012 · Cited by 2,093
Self-citationThe prevention and treatment of missing data in clinical trials
Little, R. J., D'Agostino, R., Cohen, M. L., Dickersin, K., Emerson, S. S., Farrar, J. T., Frangakis, C., Hogan, J. W., Molenberghs, G., Murphy, S. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmsr1203730 · Cited by 1,884
Treatment of Pulmonary Arterial Hypertension
Humbert, M., Sitbon, O., & Simonneau, G. (2004) · New England Journal of Medicine · doi:10.1056/nejmra040291 · Cited by 1,707
Self-citationVerweij, J., Casali, P. G., Zalcberg, J., LeCesne, A., Reichardt, P., Blay, J.-Y., Issels, R., van Oosterom, A., Hogendoorn, P. C., Van Glabbeke, M., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17098-0 · Cited by 1,665
Pulmonary Arterial Hypertension
Farber, H. W., & Loscalzo, J. (2004) · New England Journal of Medicine · doi:10.1056/nejmra035488 · Cited by 1,463
Humbert, M., Sitbon, O., Chaouat, A., Bertocchi, M., Habib, G., Gressin, V., Yaïci, A., Weitzenblum, E., Cordier, J.-F., Chabot, F., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.911818 · Cited by 1,399
Self-citationTadalafil Therapy for Pulmonary Arterial Hypertension
Galiè, N., Brundage, B. H., Ghofrani, H. A., Oudiz, R. J., Simonneau, G., Safdar, Z., Shapiro, S., White, R. J., Chan, M., Beardsworth, A., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.839274 · Cited by 1,103
Self-citationGaliè, N., Olschewski, H., Oudiz, R. J., Torres, F., Frost, A., Ghofrani, H. A., Badesch, D. B., McGoon, M. D., McLaughlin, V. V., Roecker, E. B., et al. (2008) · Circulation · doi:10.1161/circulationaha.107.742510 · Cited by 1,083
Self-citationReversal of experimental pulmonary hypertension by PDGF inhibition
Schermuly, R. T. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24838 · Cited by 1,058
Screening, Early Detection, and Diagnosis of Pulmonary Arterial Hypertension
McGoon, M., Gutterman, D., Steen, V., Barst, R., McCrory, D. C., Fortin, T. A., & Loyd, J. E. (2004) · Chest · doi:10.1378/chest.126.1_suppl.14s · Cited by 932
Self-citationCellular and Molecular Basis of Pulmonary Arterial Hypertension
Morrell, N. W., Adnot, S., Archer, S. L., Dupuis, J., Lloyd Jones, P., MacLean, M. R., McMurtry, I. F., Stenmark, K. R., Thistlethwaite, P. A., Weissmann, N., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.04.018 · Cited by 819
Self-citationSurvival in incident and prevalent cohorts of patients with pulmonary arterial hypertension
Humbert, M., Sitbon, O., Yaïci, A., Montani, D., O'Callaghan, D. S., Jaïs, X., Parent, F., Savale, L., Natali, D., Günther, S., et al. (2010) · European Respiratory Journal · doi:10.1183/09031936.00057010 · Cited by 674
Self-citationPulmonary Arterial Hypertension in Patients Treated by Dasatinib
Montani, D., Bergot, E., Günther, S., Savale, L., Bergeron, A., Bourdin, A., Bouvaist, H., Canuet, M., Pison, C., Macro, M., et al. (2012) · Circulation · doi:10.1161/circulationaha.111.079921 · Cited by 659
Self-citationRandomized Study of Adding Inhaled Iloprost to Existing Bosentan in Pulmonary Arterial Hypertension
McLaughlin, V. V., Oudiz, R. J., Frost, A., Tapson, V. F., Murali, S., Channick, R. N., Badesch, D. B., Barst, R. J., Hsu, H. H., & Rubin, L. J. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200603-358oc · Cited by 626
Self-citationAddition of Inhaled Treprostinil to Oral Therapy for Pulmonary Arterial Hypertension
McLaughlin, V. V., Benza, R. L., Rubin, L. J., Channick, R. N., Voswinckel, R., Tapson, V. F., Robbins, I. M., Olschewski, H., Rubenfire, M., & Seeger, W. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.01.027 · Cited by 566
Self-citationImatinib for the Treatment of Pulmonary Arterial Hypertension
Ghofrani, H. A., Seeger, W., & Grimminger, F. (2005) · New England Journal of Medicine · doi:10.1056/nejmc051946 · Cited by 492
Self-citationBarst, R. J., Langleben, D., Badesch, D., Frost, A., Lawrence, E. C., Shapiro, S., Naeije, R., & Galie, N. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.01.057 · Cited by 478
Self-citationPlatelet-derived Growth Factor Expression and Function in Idiopathic Pulmonary Arterial Hypertension
Perros, F., Montani, D., Dorfmüller, P., Durand-Gasselin, I., Tcherakian, C., Le Pavec, J., Mazmanian, M., Fadel, E., Mussot, S., Mercier, O., et al. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200707-1037oc · Cited by 472
Self-citationImatinib in Pulmonary Arterial Hypertension Patients with Inadequate Response to Established Therapy
Ghofrani, H. A., Morrell, N. W., Hoeper, M. M., Olschewski, H., Peacock, A. J., Barst, R. J., Shapiro, S., Golpon, H., Toshner, M., Grimminger, F., et al. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201001-0123oc · Cited by 384
Self-citationHumbert, M., Monti, G., Fartoukh, M., Magnan, A., Brenot, F., Rain, B., Capron, F., Galanaud, P., Duroux, P., Simonneau, G., et al. (1998) · European Respiratory Journal · doi:10.1183/09031936.98.11030554 · Cited by 306
Self-citationMathai, S. C., Puhan, M. A., Lam, D., & Wise, R. A. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201203-0480oc · Cited by 276
Long term imatinib treatment in pulmonary arterial hypertension
Souza, R. (2006) · Thorax · doi:10.1136/thx.2006.064097 · Cited by 165
Imatinib Mesylate in the Treatment of Refractory Idiopathic Pulmonary Arterial Hypertension
Patterson, K. C., Weissmann, A., Ahmadi, T., & Farber, H. W. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-2-200607180-00020 · Cited by 148
Gomberg‐Maitland, M., Maitland, M. L., Barst, R. J., Sugeng, L., Coslet, S., Perrino, T. J., Bond, L. R., Lacouture, M. E., Archer, S. L., & Ratain, M. J. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.217 · Cited by 109
Self-citationNakamura, K., Akagi, S., Ogawa, A., KUSANO, K. F., Matsubara, H., Miura, D., Fuke, S., Nishii, N., Nagase, S., Kohno, K., et al. (2011) · International Journal of Cardiology · doi:10.1016/j.ijcard.2011.02.024 · Cited by 70
Major bleeding with vitamin K antagonist anticoagulants in pulmonary hypertension
Henkens, I. R., Hazenoot, T., Boonstra, A., Huisman, M. V., & Noordegraaf, A. V. (2012) · European Respiratory Journal · doi:10.1183/09031936.00039212 · Cited by 68
Tyrosine Kinase Inhibitors Are Potent Acute Pulmonary Vasodilators in Rats
Abe, K., Toba, M., Alzoubi, A., Koubský, K., Ito, M., Ota, H., Gairhe, S., Gerthoffer, W. T., Fagan, K. A., McMurtry, I. F., et al. (2011) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2010-0371oc · Cited by 64
Cited by
Zamorano, J. L., Lancellotti, P., Rodriguez Muñoz, D., Aboyans, V., Asteggiano, R., Galderisi, M., Habib, G., Lenihan, D. J., Lip, G. Y. H., Lyon, A. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw211 · Cited by 2,544
Zamorano, J. L., Lancellotti, P., Rodriguez Muñoz, D., Aboyans, V., Asteggiano, R., Galderisi, M., Habib, G., Lenihan, D. J., Lip, G. Y. H., Lyon, A. R., et al. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.654 · Cited by 1,795
Right Heart Adaptation to Pulmonary Arterial Hypertension
Vonk-Noordegraaf, A., Haddad, F., Chin, K. M., Forfia, P. R., Kawut, S. M., Lumens, J., Naeije, R., Newman, J., Oudiz, R. J., Provencher, S., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.10.027 · Cited by 982
Self-citationRisk stratification and medical therapy of pulmonary arterial hypertension
Galiè, N., Channick, R. N., Frantz, R. P., Grünig, E., Jing, Z. C., Moiseeva, O., Preston, I. R., Pulido, T., Safdar, Z., Tamura, Y., et al. (2019) · European Respiratory Journal · doi:10.1183/13993003.01889-2018 · Cited by 819
Self-citationNew developments in mast cell biology
Kalesnikoff, J., & Galli, S. J. (2008) · Nature Immunology · doi:10.1038/ni.f.216 · Cited by 748
Metadata
- Authors
- Hoeper, M. M., Barst, R. J., Bourge, R. C., Feldman, J., Frost, A. E., Galié, N., Gómez-Sánchez, M. A., Grimminger, F., Grünig, E., Hassoun, P. M., Morrell, N. W., Peacock, A. J., Satoh, T., Simonneau, G., Tapson, V. F., Torres, F., Lawrence, D., Quinn, D. A., & Ghofrani, H.-A.
- Venue
- Circulation
- Published
- 2013-03-12
- Volume
- 127
- Issue
- 10
- Pages
- 1128-1138
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W1979770196
- Cited by
- 574
- References
- 34
- FWCI
- 52.13
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.